Healthcare Industry News: proteasome
News Release - February 25, 2008
Proteolix Names Matthew Ferguson to Newly-Created Position of Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., Feb. 25 (HSMN NewsFeed) -- Proteolix, Inc., a clinical-stage company engaged in the development of novel pharmaceutical therapies for the treatment of cancer and immunological conditions, announced that it has appointed Matthew Ferguson to the new position of Chief Financial Officer. Mr. Ferguson brings extensive experience arranging financing and managing rapid growth in both life sciences and technology companies.Before joining Proteolix, Mr. Ferguson served as CFO at medical device maker FoxHollow Technologies, Inc. During his five-year tenure there, the company advanced its flagship technology for the treatment of peripheral arterial disease through development, FDA approval and commercial launch in the U.S. Mr. Ferguson led FoxHollow's 2004 initial public offering and played a significant role in the company's 2007 merger with ev3 Inc. Mr. Ferguson previously held a variety of financial management and business development positions at ChannelPoint, Inc. and Hewlett-Packard. Mr. Ferguson holds an M.B.A. from the University of California at Berkeley and M.S. and B.S. degrees in engineering from the University of Pennsylvania and Stanford University, respectively.
"The Proteolix opportunity is driven by an expert team, a large unmet clinical need and compelling early clinical results for carfilzomib," commented Mr. Ferguson. "I look forward to contributing my skills and experience towards our dual goals of improving the lives of patients and generating substantial returns for our shareholders."
About Proteolix
Proteolix, Inc. is a privately-held biopharmaceutical company, headquartered in South San Francisco, and dedicated to discovering, developing and commercializing pharmaceutical therapies that target certain cancers and immunological conditions by inhibiting the proteasome and thereby disrupting protein turnover in cells. In Phase I clinical studies, the Company's lead product candidate, carfilzomib (PR-171), demonstrated single-agent activity in the treatment of relapsed and refractory multiple myeloma. Carfilzomib is currently in Phase II clinical studies to evaluate its safety and efficacy in multiple myeloma, lymphoma and solid tumor malignancies. Proteolix is also developing a pipeline of next-generation proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor. For more information, please visit the Company's website at http://www.proteolix.com.
Source: Proteolix
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
